Effect of Atorvastatin on liver function in patients with chronic hepatitis B
Phase 3
- Conditions
- chronic hepatitis.Chronic persistent hepatitis
- Registration Number
- IRCT2017010631252N3
- Lead Sponsor
- Qom University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Patients between 18 and 75 years old with chronic hepatitis B for more than 6 months and dysfunction in liver function, serum LDL more than 90 mg/dl
Exclusion criteria: Patients with hepatitis B less than 6 months, Inactive carriers of hepatitis B, Patients with no fibrosis and cirrhosis, Patients with decompensated cirrhosis, Patients with chronic liver disease such as willson and hemochromatosis, Patients with hepatic cell carcinoma, Patients with other malignancies, Patients with co-infection and superinfection of HIV ,HCV or HDV, Patients that were treated with Atorvastatin, Pregnant and lactating women, Increasing of liver enzymes 2 times of normal range after 1 months of treatment.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sevirity of fibrosis. Timepoint: Six months after begining intervention. Method of measurement: kpa with fibroscan.;Liver function. Timepoint: Six months after intervention. Method of measurement: Child score.
- Secondary Outcome Measures
Name Time Method iver enzymes levels. Timepoint: Six month after begining of intervention. Method of measurement: Blood levels with IU/ml.